Skip to main content
EJNMMI Research

Table 2 Pulmonary function, SUVmax and TLuG at baseline and after 26 weeks infliximab treatment, n = 27; mean ± SD

From: Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis

 

Baseline

After 26 weeks infliximab

Change

p value

FVC (% predicted)

75.1 ± 18.4

79.7 ± 19.9

+ 4.6 ± 8.4

0.009

FEV1 (% predicted)

58.6 ± 17.9

63.6 ± 20.5

+ 5.1 ± 6.8

0.001

DLCOc (% predicted)a

55.5 ± 17.9

57.9 ± 16.9

+ 2.4 ± 6.8

0.100

SUVmax

8.2 ± 4.7

3.1 ± 2.9

− 5.1 ± 5.1

< 0.001

TLuG

5395 ± 3216

2641 ± 952

− 2755 ± 3064

< 0.001

  1. FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, DLCOc diffusing capacity of the lung for carbon monoxide corrected for haemoglobin, SUVmax maximum standardized uptake value, TLuG total lung glycolysis
  2. aThree missing values
Back to article page